Related Experiment Video

Updated: Aug 12, 2026

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay
19:34

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay

Published on: April 3, 2009

Toxicological evaluation of oligonucleotide therapeutics

J K Marquis1, J M Grindel

  • 1GelTex Pharmaceuticals, 153 Second Avenue, Waltham, MA 02451, USA. jmarquis@geltex.com

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed

Insights

Phosphorothioate oligonucleotides require careful safety evaluation due to potential systemic effects. This review guides preclinical scientists on assessing target organ toxicity for safe clinical trial dosing.

Area of Science:

  • Pharmacology and Toxicology
  • Drug Development
  • Oligonucleotide Therapeutics

Background:

  • Phosphorothioate oligonucleotides (PS-ONs) present unique preclinical development challenges.
  • Systemic exposure can lead to significant functional, laboratory, and histopathological changes.
  • Understanding the polyanionic nature is key to interpreting safety data.

Purpose of the Study:

  • To provide guidance on the safety evaluation of phosphorothioate oligonucleotides.
  • To assist preclinical scientists in navigating the complexities of PS-ON development.
  • To establish a framework for determining safe starting doses for clinical trials.

Main Methods:

  • Review of historical data for related polyanionic structures.
  • Description of dose-related responses in various laboratory species.
  • Identification of major target organs and their toxicological profiles.

Main Results:

  • Liver, kidneys, and immune system are identified as primary target organs.
  • Dose-dependent adverse effects are observed across different species.
  • Understanding organ-specific responses is crucial for safety assessment.

Conclusions:

  • Systematic safety evaluation is essential for phosphorothioate oligonucleotides.
  • Target organ toxicity data informs the determination of safe clinical starting doses.
  • This review offers an experimental perspective for preclinical drug development.

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...